Repligen (RGEN) Projected to Post Earnings on Tuesday

Repligen (NASDAQ:RGEN - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, July 29th. Analysts expect the company to announce earnings of $0.40 per share and revenue of $174.62 million for the quarter. Repligen has set its FY 2025 guidance at 1.630-1.720 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The business's revenue was up 10.4% compared to the same quarter last year. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Stock Performance

Shares of RGEN traded up $0.92 during midday trading on Friday, reaching $122.79. 176,742 shares of the stock were exchanged, compared to its average volume of 756,916. The business's 50-day moving average price is $123.68 and its 200 day moving average price is $137.66. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. Repligen has a twelve month low of $102.96 and a twelve month high of $182.52. The company has a market capitalization of $6.90 billion, a price-to-earnings ratio of -272.84, a PEG ratio of 2.18 and a beta of 1.11.

Hedge Funds Weigh In On Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its holdings in Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock worth $18,067,000 after acquiring an additional 20,375 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Repligen by 3,850.6% during the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock worth $814,000 after purchasing an additional 6,238 shares during the period. Finally, AQR Capital Management LLC acquired a new position in shares of Repligen during the 1st quarter worth $262,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Barclays began coverage on shares of Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price on the stock. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 price objective on the stock in a research note on Tuesday. Canaccord Genuity Group dropped their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $169.92.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.